Guselkumab 200mg/2ml solution for injection pre-filled disposable devices
Requires a prescription from a doctor or prescriber
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Guselkumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Guselkumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Guselkumab on the MHRA register
Tremfya PushPen 200mg/2ml solution for injection pre-filled pens
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Guselkumab
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(14)
Guselkumab for treating moderate to severe plaque psoriasis (TA521)
Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)
Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Risankizumab for treating moderate to severe plaque psoriasis (TA596)
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Spondyloarthritis in over 16s: diagnosis and management (NG65)
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Ulcerative colitis: management (NG130)
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Psoriasis: assessment and management (CG153)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
15 to 18 days
Mechanism
Guselkumab targets the p19 alpha subunit of IL-23.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
100mg
Half-life
15 to 18 days
[L52700]
Volume of distribution
13.5 L
[L52700]
Metabolism
[L52700]…
Elimination
Clearance
0.516 L
[L52700]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
- the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy.
[L52700]
- the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis.
[L52700]
- the treatment of adults with moderately to severely active ulcerative colitis.
[L52700]
- the treatment of adults with moderately to severely active Crohn’s disease.
[L52700]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 681 interactions
[L52700]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L52700]
[L52700]
[L52700]
[L52700]
[L52700]
Proteins and enzymes this drug interacts with in the body
PMID:11114383
Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4 .
PMID:29287995 PMID:32474165 PMID:33606986
This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A .
PMID:12023369
In turn, participates in the early and effective intracellular bacterial clearance .
PMID:32474165
Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells PMID:17676044
ATC L04AC16
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Guselkumab
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: